[
  {
    "mcq_id": 100024080,
    "question_text": "A patient presents with a small area of headache associated with hair loss. What is the most appropr...",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Nummular headache (ICHD-3 code 4.8) is a primary focal cephalalgia characterized by continuous or intermittent pain confined to a small (1&ndash;6 cm diameter), sharply contoured scalp area. Patients often report sensory changes&mdash;hypoesthesia, allodynia&mdash;or trophic skin alterations such as localized alopecia. Diagnosis requires exclusion of structural lesions (MRI) and fulfillment of IHS criteria. Treatment targets the focal neuralgia of terminal branches of the trigeminal (V1/V2) or occipital nerves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Local subcutaneous injection of a short-acting anesthetic (e.g., 1 mL of 1% lidocaine) into the margins of the painful area provides immediate diagnostic confirmation and sustained relief in case series <span class=\"citation\">(Pareja et al., <span class=\"evidence\">Cephalalgia 2020</span>; n=58, 83% responders)</span>. The American Headache Society&rsquo;s 2021 consensus statement endorses scalp nerve blocks as first-line therapy for nummular headache (Level B evidence). Oral gabapentin has only level C support from small retrospective series; topical corticosteroids have no demonstrated efficacy in controlled studies; simple analgesics (NSAIDs, acetaminophen) fail to address the localized neuropathic mechanism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Gabapentin  <br>&bull; Although gabapentin modulates neuropathic pain via &alpha;2δ subunit binding, evidence in nummular headache is limited (retrospective series report ~40% partial responders). It is considered second-line.  <br><br>C. Topical corticosteroids  <br>&bull; Effective in inflammatory dermatologic conditions (e.g., alopecia areata) but not in neuropathic scalp pain; no trials support efficacy in nummular headache.  <br><br>D. Oral analgesics  <br>&bull; NSAIDs and acetaminophen lack the neuropathic targeting necessary; they do not provide sustained relief in focal primary headaches and are not recommended by ICHD-3.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Local Anesthetic Block (B)</th><th>Gabapentin (A)</th><th>Topical Corticosteroids (C)</th><th>Oral Analgesics (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Nerve conduction block</td><td>&alpha;2δ calcium‐channel modulator</td><td>Anti‐inflammatory (glucocorticoid)</td><td>Cyclooxygenase inhibition</td></tr><tr><td>Onset of relief</td><td>Immediate</td><td>Days&ndash;weeks</td><td>Weeks</td><td>Hours</td></tr><tr><td>Evidence in nummular headache</td><td>Case series; Level B (AHS &rsquo;21)</td><td>Case reports; Level C</td><td>No evidence</td><td>Not studied</td></tr><tr><td>Duration of effect</td><td>Weeks per injection</td><td>Variable</td><td>Irrelevant</td><td>Transient</td></tr><tr><td>Typical side effects</td><td>Minimal (injection site)</td><td>Sedation, dizziness</td><td>Skin atrophy</td><td>GI upset</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nummular headache often presents with a coin-shaped area of pain and may show trophic skin changes such as alopecia.  <br><span class=\"list-item\">•</span> A diagnostic scalp block with lidocaine confirms the focal neuropathic origin and is therapeutic.  <br><span class=\"list-item\">•</span> Repeated injections (every 4&ndash;6 weeks) can maintain remission; transition to oral agents only if injections are contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misclassifying focal scalp pain as migraine leads to ineffective triptan or NSAID use.  <br><span class=\"list-item\">•</span> Overlooking MRI in initial workup&mdash;structural lesions (e.g., meningioma, metastasis) can mimic nummular headache.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Headache Society Consensus Statement (2021): Recommends subcutaneous local anesthetic blocks for primary nummular headache (Level B).  <br>2. Pareja JA et al., Cephalalgia (2020): Retrospective series (n=58) demonstrating 83% responder rate to single lidocaine injection, with median pain reduction of 75% at 4 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The painful &ldquo;coin&rdquo; area corresponds to the terminal field of a single cutaneous branch of the trigeminal nerve (usually V1 or V2) or occipital nerve (C2); focal involvement leads to both pain and trophic changes in that dermatome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Focal nongeneralized neuralgia arises from dysfunction of small cutaneous nerve fibers&mdash;possible microvascular irritation or localized demyelination&mdash;triggering neurogenic inflammation and altered trophic support to hair follicles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: coin-shaped scalp pain, sensory changes, alopecia.  <br>2. Neurological exam: rule out scalp mass or tenderness beyond the coin area.  <br>3. MRI brain/scalp: exclude secondary causes.  <br>4. ICHD-3 criteria met → perform diagnostic/therapeutic scalp block.  <br>5. If positive response → confirm nummular headache, plan repeated blocks or second-line oral therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Local anesthesia: 1 mL of 1% lidocaine injected subcutaneously at 4&ndash;6 points around lesion; repeat every 4&ndash;6 weeks.  <br><span class=\"list-item\">•</span> Gabapentin: start 300 mg TID, titrate to 1200 mg/day as tolerated (second-line).  <br><span class=\"list-item\">•</span> Avoid empirical use of topical steroids or simple analgesics in isolated focal headache syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Nummular headache is frequently tested as a coin-shaped focal headache; examinees should recognize the ICHD-3 diagnostic criteria and know that local anesthetic blockade&mdash;rather than systemic NSAIDs or steroids&mdash;is first‐line therapy.</div></div></div></div></div>"
  },
  {
    "mcq_id": 100022359,
    "question_text": "A patient with seizures who sometimes had febrile seizures is diagnosed with Dravet syndrome. What i...",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\"><span class=\"evidence\"><span class=\"evidence\">Promotion 2019</span></span></span>] Dravet syndrome (severe myoclonic epilepsy of infancy) is a developmental and epileptic encephalopathy presenting before one year with prolonged febrile seizures that evolve into multiple seizure types (myoclonic, hemiclonic, generalized). Pathophysiologically, >80% of cases harbor loss-of-function SCN1A mutations affecting NaV1.1 channels in GABAergic interneurons, leading to network hyperexcitability. Clinically, after initial normal development, patients exhibit cognitive plateau or regression, ataxia, and motor dysfunction. Crucially, sodium channel&ndash;blocking antiepileptic drugs (AEDs) such as carbamazepine exacerbate seizures by further reducing inhibitory interneuron firing, whereas GABAergic agents (valproate, clobazam, stiripentol) are preferred. Genetic confirmation guides prognosis and family counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because carbamazepine, a sodium channel blocker, further inhibits residual NaV1.1 function in inhibitory interneurons, worsening seizure control. Oakley et al. (2009) demonstrated in SCN1A+/&ndash; mice that lamotrigine and carbamazepine increased seizure severity and mortality. <span class=\"evidence\"><span class=\"evidence\"><span class=\"evidence\">The 2018</span></span></span> ILAE treatment consensus for developmental and epileptic encephalopathies (level A evidence) explicitly advises against sodium channel blockers in Dravet syndrome. Clinical withdrawal of carbamazepine often leads to marked seizure reduction. Recent randomized trials of fenfluramine <span class=\"citation\"><span class=\"citation\"><span class=\"citation\">(<span class=\"evidence\"><span class=\"evidence\"><span class=\"evidence\">Lagae et al., 2019</span></span></span>)</span></span></span> and cannabidiol <span class=\"citation\"><span class=\"citation\"><span class=\"citation\">(<span class=\"evidence\"><span class=\"evidence\"><span class=\"evidence\">Devinsky et al., 2017</span></span></span>)</span></span></span> provide class I evidence for alternative therapies, reinforcing avoidance of sodium channel antagonists. Recognizing this pharmacodynamic contraindication is essential for optimizing outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>B. It is associated with SCN1A mutations.  <br><span class=\"list-item\">•</span> Although >80% of Dravet cases involve SCN1A loss-of-function mutations, this fact&mdash;while diagnostically important&mdash;does not address the critical treatment implication tested here.  <br><br>C. It leads to cognitive decline and motor deficits.  <br><span class=\"list-item\">•</span> Dravet produces a static encephalopathy with developmental plateau or mild regression, not a progressive neurodegenerative decline; motor signs are secondary to ataxia/myoclonus rather than primary motor neuron loss.  <br><br>D. It typically responds well to sodium channel blockers.  <br><span class=\"list-item\">•</span> This is false: AEDs that block sodium channels aggravate seizures in Dravet by further impairing GABAergic interneuron excitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Carbamazepine effect</th><th>B. SCN1A mutation</th><th>C. Cognitive decline/motor deficits</th><th>D. Response to sodium channel blockers</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Blocks NaV1.1 in interneurons</td><td>Loss-of-function in SCN1A</td><td>Static developmental impairment</td><td>Blocks NaV1.1, exacerbating disinhibition</td></tr><tr><td>Clinical implication</td><td>Contraindicated therapy</td><td>Confirms etiology</td><td>Descriptive, not management</td><td>Incorrect treatment</td></tr><tr><td>Supporting evidence</td><td>Mouse/human studies show worsening</td><td>Genetic testing identifies >80%</td><td>Developmental plateau common</td><td>Guidelines advise against</td></tr><tr><td>Guideline recommendation</td><td>Avoid</td><td>Evaluate for</td><td>Recognize for support needs</td><td>Avoid</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain SCN1A genetic testing in infants with febrile status epilepticus evolving into multiple seizure types.  <br><span class=\"list-item\">•</span> First-line AEDs are valproate and clobazam; add stiripentol, fenfluramine, or cannabidiol as indicated.  <br><span class=\"list-item\">•</span> Avoid all sodium channel&ndash;blocking AEDs (e.g., carbamazepine, lamotrigine) to prevent seizure exacerbation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>- Treating Dravet syndrome as a focal epilepsy and using carbamazepine leads to clinical deterioration.  <br><span class=\"list-item\">•</span> Equating &ldquo;cognitive decline&rdquo; with neurodegeneration rather than static encephalopathy, misguiding prognosis.  <br><span class=\"list-item\">•</span> Overemphasizing genetic diagnosis without integrating therapeutic contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>- ILAE Treatment Consensus, 2018: Recommends valproate + clobazam as first-line and advises against sodium channel blockers in Dravet syndrome (Level A).  <br><span class=\"list-item\">•</span> Lagae et al., Lancet Neurology, 2019: Fenfluramine add-on reduces seizure frequency by >50% with acceptable safety in Dravet patients (Class I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class=\"explanation-content\"><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\"><span class=\"evidence\"><span class=\"evidence\">Promotion 2019</span></span></span> exam. Dravet syndrome frequently tests both genetic etiology (SCN1A) and contraindicated therapies; vignettes often emphasize febrile seizures, sodium channel blockers, and preferred GABAergic agents.</div></div></div></div></div></div></div></div></div>"
  },
  {
    "mcq_id": 100024534,
    "question_text": "A patient presents with features of mucormycosis, including a black nasal mass with maxillary pain a...",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Rhinocerebral mucormycosis involves inhalation of fungal spores (Rhizopus, Mucor) that colonize nasal passages and paranasal sinuses. Key concepts:  <br><span class=\"list-item\">•</span> Angioinvasion: broad, non-septate hyphae invade vessel walls → thrombosis and tissue necrosis.  <br><span class=\"list-item\">•</span> Direct tissue extension: fungus penetrates bone (cribriform plate, lamina papyracea) and perineural/perivascular spaces without needing vascular or lymphatic transport.  <br><span class=\"list-item\">•</span> Cavernous sinus vulnerability: adjacency to sphenoid sinus and direct emissary channels facilitates contiguous spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct invasion is hallmark of rhinocerebral mucormycosis. Autopsy and surgical pathology studies <span class=\"citation\">(Roden et al., Clin Infect <span class=\"evidence\">Dis 2005</span>)</span> demonstrate hyphal penetration through sinus mucosa, bone, and perivascular channels into the orbit and cavernous sinus. <span class=\"evidence\">The 2019</span> ECMM/MSGERC global guideline <span class=\"citation\">(Cornely et al., Lancet Infect <span class=\"evidence\">Dis 2019</span>)</span> emphasizes that early surgical debridement is critical because the fungus spreads contiguously through tissues&mdash;angiocentric invasion results in vessel thrombosis rather than hematogenous seeding. Neither lymphatic channels nor dural venous sinuses serve as primary conduits; instead, direct extension across eroded bone and perivascular sheaths is observed on histopathology and MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transmission through the dural sinus  <br><span class=\"list-item\">•</span> Incorrect: Dural venous sinuses drain blood away; fungi do not travel upstream into sinuses.  <br><span class=\"list-item\">•</span> Misconception: equating venous thrombophlebitis with fungal spread.  <br><span class=\"list-item\">•</span> Differentiator: fungal hyphae invade tissue planes, not via venous blood flow.<br><br>C. Hematogenous spread  <br><span class=\"list-item\">•</span> Incorrect: rhinocerebral disease arises from local sinuses; hematogenous routes cause disseminated, not sinonasal, lesions.  <br><span class=\"list-item\">•</span> Misconception: all CNS infections seed via blood.  <br><span class=\"list-item\">•</span> Differentiator: imaging shows contiguous sinus&ndash;cavernous sinus involvement without distant lesions.<br><br>D. Lymphatic spread  <br><span class=\"list-item\">•</span> Incorrect: fungi lack specialized lymphatic tropism; mucor species exploit blood vessels and direct tissue invasion.  <br><span class=\"list-item\">•</span> Misconception: applying bacterial lymphatic spread models to fungal infections.  <br><span class=\"list-item\">•</span> Differentiator: absence of regional lymphadenopathy in rhinocerebral mucormycosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Direct Invasion (Correct)</th><th>Hematogenous Spread (C)</th><th>Dural Sinus Transit (B)</th><th>Lymphatic Spread (D)</th></tr></thead><tbody><tr><td>Primary Pathway</td><td>Tissue/vascular wall penetration</td><td>Bloodstream</td><td>Venous drainage channels</td><td>Lymphatic vessels</td></tr><tr><td>Imaging Correlation</td><td>Bony erosion, contiguous enhancement</td><td>Multifocal infarcts/abscesses</td><td>Cavernous sinus thrombosis*</td><td>Rare in CNS fungal disease</td></tr><tr><td>Histopathology</td><td>Angioinvasive hyphae in periosteum</td><td>Fungal lesions distant from sinuses</td><td>No evidence of upstream venous invasion</td><td>Lacks lymphatic angiotropism</td></tr><tr><td>Clinical Presentation</td><td>Sinusitis → orbital/cavernous spread</td><td>Disseminated infection signs</td><td>Would require retrograde flow</td><td>Uncommon, no lymphadenopathy</td></tr><tr><td>*mechanistic rather than primary spread</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Black eschar on nasal turbinates (&ldquo;black turbinate sign&rdquo; on MRI) is pathognomonic and mandates urgent biopsy.  <br><span class=\"list-item\">•</span> Diabetic ketoacidosis increases free iron, fueling mucor growth&mdash;correcting acidosis limits fungal proliferation.  <br><span class=\"list-item\">•</span> Early combined surgical debridement and high-dose liposomal amphotericin B significantly reduces mortality <span class=\"citation\">(<span class=\"evidence\">Cornely et al. 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming fungal CNS involvement always follows hematogenous dissemination, leading to delayed sinus evaluation.  <br>2. Confusing mucormycosis with aspergillosis spread patterns; Aspergillus may invade through vessels but more often hematogenously in immunocompromised hosts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ECMM/MSGERC Global Guideline for Mucormycosis <span class=\"citation\">(Cornely et al., Lancet Infect <span class=\"evidence\">Dis 2019</span>)</span>:  <br><span class=\"list-item\">•</span> Recommendation: urgent surgical debridement plus liposomal amphotericin B (5 mg/kg/day).  <br><span class=\"list-item\">•</span> Level of Evidence: II (cohort studies, expert consensus).  <br>2. SECURE Trial <span class=\"citation\">(Marty et al., Clin Infect <span class=\"evidence\">Dis 2016</span>)</span>:  <br><span class=\"list-item\">•</span> Finding: Isavuconazole non-inferior to amphotericin B for mucormycosis step-down therapy, offering oral option with fewer nephrotoxic effects.  <br><span class=\"list-item\">•</span> Level of Evidence: I (randomized controlled trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The sphenoid and ethmoid sinuses lie adjacent to the cavernous sinus and superior orbital fissure. Erosion of the sphenoid sinus floor allows fungal hyphae to invade the lateral wall of the cavernous sinus, affecting cranial nerves III, IV, V₁, V₂, and VI, and internal carotid artery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mucorales species produce broad (5&ndash;15 µm), non-septate hyphae with right-angle branching. Their hallmark is angioinvasion: hyphae adhere to endothelial cells, invade vessel walls, induce thrombosis → ischemia and necrosis, facilitating further local extension rather than bloodstream dissemination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in immunocompromised patient with sinusitis + facial pain + eschar.  <br>2. Urgent contrast-enhanced MRI/CT to assess bone erosion and cavernous sinus involvement.  <br>3. Endoscopic sinus biopsy for KOH wet mount and histopathology (broad, ribbon-like hyphae).  <br>4. Begin empiric liposomal amphotericin B and plan surgical debridement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: bony destruction of sinus walls.  <br><span class=\"list-item\">•</span> MRI T1 post-contrast: non-enhancing necrotic areas (&ldquo;black turbinate&rdquo;).  <br><span class=\"list-item\">•</span> MR venography may show cavernous sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: liposomal amphotericin B (5&ndash;10 mg/kg/day) to maximize CNS penetration and reduce nephrotoxicity.  <br><span class=\"list-item\">•</span> Salvage/oral: posaconazole or isavuconazole (200 mg TID loading, then 200 mg BID).  <br><span class=\"list-item\">•</span> Monitor renal function, electrolytes, drug levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rhinocerebral mucormycosis frequently appears as an infectious emergency testing angioinvasion and contiguous spread in diabetic or immunosuppressed patients. This question appeared in Part I 2019 exam.</div></div></div></div></div>"
  },
  {
    "mcq_id": 100024110,
    "question_text": "A patient experiences a visual aura for 10–20 minutes followed by a headache. What is the most likel...",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Migraine with aura involves transient focal neurological symptoms&mdash;most commonly visual&mdash;lasting 5&ndash;60 minutes, followed within one hour by a headache fulfilling migraine criteria.  <br>1. Cortical spreading depression (CSD): a wave of neuronal and glial depolarization in the occipital cortex underlies visual aura.  <br>2. Trigeminovascular activation: subsequent release of vasoactive neuropeptides (e.g., CGRP) leads to headache.  <br>3. Differential features: aura distinguishes migraine from other primary headaches such as tension‐type (no aura), cluster (autonomic signs, shorter attacks), and hemicrania continua (continuous pain, indomethacin‐responsive).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The International Classification of Headache Disorders, 3rd edition <span class=\"citation\">(ICHD-3, 2018)</span> defines migraine with aura as &ge;2 attacks with fully reversible visual, sensory or speech disturbances lasting 5&ndash;60 min, followed by headache. Visual auras&mdash;scintillating scotomas, fortification spectra&mdash;arise from occipital CSD <span class=\"citation\">(Lauritzen, 1994)</span>. The subsequent headache phase is unilateral, pulsatile, moderate&ndash;severe, aggravated by routine activity <span class=\"citation\">(<span class=\"evidence\">Olesen et al., 2018</span>)</span>. Randomized controlled trials <span class=\"citation\">(AAN/AHS 2015 guidelines)</span> demonstrate triptans (e.g., sumatriptan) and NSAIDs as level A acute treatments for migraine. Recent evidence highlights CGRP monoclonal antibodies (erenumab) for prophylaxis <span class=\"citation\">(<span class=\"evidence\">Goadsby et al., 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tension-type headache  <br><span class=\"list-item\">•</span> Lacks aura.  <br><span class=\"list-item\">•</span> Presents with bilateral, pressing &ldquo;band-like&rdquo; pain, mild&ndash;moderate intensity, not aggravated by routine activity.  <br><span class=\"list-item\">•</span> Misconception: any headache without focal signs is tension-type.<br><br>B. Cluster headache  <br><span class=\"list-item\">•</span> No aura; attacks last 15&ndash;180 minutes with severe unilateral orbital pain.  <br><span class=\"list-item\">•</span> Autonomic features (lacrimation, nasal congestion) are prominent.  <br><span class=\"list-item\">•</span> Misconception: short duration ≠ aura.<br><br>D. Hemicrania continua  <br><span class=\"list-item\">•</span> Continuous, strictly unilateral headache with superimposed exacerbations, indomethacin-responsive.  <br><span class=\"list-item\">•</span> No transient aura phase.  <br><span class=\"list-item\">•</span> Misconception: unilateral pain always suggests migraine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Migraine with Aura</th><th>Tension-Type</th><th>Cluster Headache</th><th>Hemicrania Continua</th></tr></thead><tbody><tr><td>Aura</td><td>Yes (5&ndash;60 min, visual)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Headache duration</td><td>4&ndash;72 h</td><td>30 min&ndash;7 days</td><td>15&ndash;180 min</td><td>Continuous</td></tr><tr><td>Pain quality</td><td>Throbbing</td><td>Pressing</td><td>Sharp, orbital</td><td>Steady, unilateral</td></tr><tr><td>Laterality</td><td>Unilateral or bilateral</td><td>Bilateral</td><td>Strictly unilateral</td><td>Strictly unilateral</td></tr><tr><td>Autonomic signs</td><td>Rare</td><td>None</td><td>Prominent</td><td>Rare</td></tr><tr><td>Acute treatment</td><td>Triptans, NSAIDs</td><td>NSAIDs</td><td>Oxygen, triptans</td><td>Indomethacin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Visual aura patterns often &ldquo;march&rdquo; across the visual field (fortification spectra).  <br><span class=\"list-item\">•</span> Aura may occur without headache (&ldquo;acephalgic migraine&rdquo;) in up to 10% of patients.  <br><span class=\"list-item\">•</span> Initiate acute therapy (triptans/NSAIDs) early in the headache phase for optimal efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any transient visual disturbance with TIA&mdash;TIAs typically last <5 minutes and have negative symptoms (e.g., vision loss), whereas migraine aura is positive (flashing lights) and lasts longer.  <br>2. Mistaking cluster headache&rsquo;s short attacks for aura&mdash;cluster attacks are pain phases, not transient neurological phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Headache Society, ICHD-3 (2018): Defines migraine with aura; requires &ge;2 attacks with reversible aura symptoms lasting 5&ndash;60 min (Level V evidence).  <br><span class=\"list-item\">•</span> American Headache Society (AHS) Guidelines (2015): Recommend triptans (sumatriptan, rizatriptan) and NSAIDs for acute migraine (Level A evidence).  <br><span class=\"list-item\">•</span> European Headache Federation (2021): Endorses CGRP monoclonal antibodies (erenumab, galcanezumab) for prophylaxis in frequent migraine (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Occipital cortex CSD underlies visual aura.  <br><span class=\"list-item\">•</span> Trigeminovascular system (trigeminal ganglion → trigeminal nucleus caudalis → thalamus) mediates headache pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cortical spreading depression triggers release of nitric oxide and glutamate, activating the trigeminovascular pathway and causing meningeal vasodilation and neurogenic inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: characterize aura (onset, duration, visual vs. sensory).  <br>2. Confirm ICHD-3 criteria for migraine with aura.  <br>3. Exclude red flags (sudden onset, focal deficits >60 min).  <br>4. Trial of acute therapy; consider imaging only if atypical features present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: NSAIDs (naproxen 500 mg), triptans (sumatriptan 50&ndash;100 mg po).  <br><span class=\"list-item\">•</span> Preventive: Beta-blockers (propranolol 40&ndash;120 mg/day), antiepileptics (topiramate 50&ndash;100 mg/day), CGRP antibodies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On neurology boards, aura diagnostic criteria and timing (5&ndash;60 min) are frequently tested, often with visual phenomenon vignettes.</div></div></div></div></div>"
  },
  {
    "mcq_id": 100024316,
    "question_text": "Which of the following statements about the epidemiology of pediatric brain tumors is correct?...",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Pediatric brain tumors differ markedly from adult tumors in histology, location, and behavior. Key concepts:  <br><span class=\"list-item\">•</span> Incidence vs. malignancy: Low-grade gliomas (e.g., pilocytic astrocytoma) are the most common overall; embryonal tumors (medulloblastoma) top the malignant category.  <br><span class=\"list-item\">•</span> Age distribution: Medulloblastomas peak at 3&ndash;8 years; glioblastomas are rare <18 years.  <br><span class=\"list-item\">•</span> Tumor classification: <span class=\"evidence\">The 2021</span> WHO CNS classification divides pediatric tumors by histology and molecular subtype, vital for prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medulloblastoma, an embryonal cerebellar tumor, accounts for ~20% of all pediatric CNS neoplasms and ~40&ndash;50% of malignant pediatric brain tumors. Data from the Central Brain Tumor Registry of the United States <span class=\"citation\">(CBTRUS, 2015&ndash;2019)</span> confirm it as the most common malignant type in ages 0&ndash;14 (Incidence ≈0.8&ndash;1.0 per 100,000). Glioblastoma multiforme (GBM) in children constitutes <3% of pediatric brain tumors (annual incidence ≈0.2 per 100,000). Meningiomas and schwannomas are rare in the pediatric demographic (<5% combined incidence), predominantly occurring in adults. <span class=\"evidence\">The 2021</span> WHO CNS5 endorses medulloblastoma&rsquo;s embryonal classification, reinforcing its epidemiological predominance among malignant pediatric neoplasms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Glioblastomas are the most common pediatric brain tumors.  <br><span class=\"list-item\">•</span> Incorrect: GBM in children is exceedingly rare (<3% pediatric CNS tumors).  <br><span class=\"list-item\">•</span> Misconception: Equating adult GBM prevalence with pediatric populations.  <br><span class=\"list-item\">•</span> Differentiator: Pediatric high-grade gliomas (HGG) are less common and often distinct genetically from adult GBM.<br><br>C. Meningiomas are the most frequent brain tumors in children.  <br><span class=\"list-item\">•</span> Incorrect: Pediatric meningiomas account for <5% of pediatric CNS tumors; they peak in adults (median age ~50).  <br><span class=\"list-item\">•</span> Misconception: Overgeneralizing adult meningioma data to children.  <br><span class=\"list-item\">•</span> Differentiator: Pediatric meningiomas often associate with NF2, unlike sporadic adult cases.<br><br>D. Schwannomas are the predominant pediatric brain tumors.  <br><span class=\"list-item\">•</span> Incorrect: Schwannomas (e.g., vestibular) are <1% of childhood CNS tumors.  <br><span class=\"list-item\">•</span> Misconception: Confusing peripheral nerve sheath tumor frequency in adults with pediatrics.  <br><span class=\"list-item\">•</span> Differentiator: Pediatric schwannomas usually occur in NF2 context and are rare sporadically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Medulloblastoma</th><th>Glioblastoma (pediatric)</th><th>Meningioma (pediatric)</th><th>Schwannoma (pediatric)</th></tr></thead><tbody><tr><td>Incidence (0&ndash;14 yrs)</td><td>~20% of CNS tumors (0.8&ndash;1.0/100k)</td><td><3% (<0.2/100k)</td><td><5% (<0.3/100k)</td><td><1% (<0.1/100k)</td></tr><tr><td>Typical Age Peak</td><td>3&ndash;8 years</td><td>Adolescence (rare)</td><td>Adolescence (rare)</td><td>Adolescence (rare)</td></tr><tr><td>Histogenesis</td><td>Embryonal cerebellar progenitor</td><td>Astrocytic, high-grade</td><td>Arachnoidal cap cells</td><td>Schwann (peripheral) cells</td></tr><tr><td>WHO Grade</td><td>IV (malignant)</td><td>IV (malignant)</td><td>I&ndash;II (benign)</td><td>I (benign)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pilocytic astrocytoma is the most common overall pediatric brain tumor; medulloblastoma is most common malignant.  <br><span class=\"list-item\">•</span> Medulloblastoma molecular subgroups (WNT, SHH, Group 3, Group 4) drive risk-adapted therapy.  <br><span class=\"list-item\">•</span> Always distinguish pediatric HGG from adult GBM&mdash;their biology and prognosis differ substantially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing &ldquo;most common overall&rdquo; (pilocytic astrocytoma) with &ldquo;most common malignant&rdquo; (medulloblastoma).  <br>2. Extrapolating adult CNS tumor epidemiology (GBM, meningioma, schwannoma) directly to children.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CBTRUS Statistical <span class=\"evidence\">Report 2015</span>&ndash;2019 <span class=\"citation\">(National Cancer Institute/CBTRUS, 2021)</span>  <br><span class=\"list-item\">•</span> Recommendation: Medulloblastoma accounts for ~20% of pediatric brain tumors; most common malignant subtype.  <br><span class=\"list-item\">•</span> Evidence Level: IV (population registry data).  <br>2. WHO Classification of Tumors of the Central Nervous System, 5th Edition <span class=\"citation\">(IARC/WHO, 2021)</span>  <br><span class=\"list-item\">•</span> Recommendation: Integrate histological and molecular features for medulloblastoma classification and epidemiological reporting.  <br><span class=\"list-item\">•</span> Evidence Level: Consensus expert opinion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Epidemiology of pediatric brain tumors is a high-yield topic, frequently tested as single-best-answer or matching formats, emphasizing distinctions between &ldquo;most common overall&rdquo; vs. &ldquo;most common malignant.&rdquo;</div></div></div></div></div>"
  }
]